Vol. 30. Núm. 2.
Páginas 90-96 (Febrero 2023)

Terapéuticaen APS
Infecciones del tracto urinario de repetición

María del Carmen Santomil PonteaErnesto José González VeigaaAroa Mayán TaboadaaEstefanía Rodríguez RomeroaEnrique Nieto Polb
Doi : https://10.1016/j.fmc.2022.08.004
Opciones
Puntos para una lectura rápida

  • •

    Las infecciones del tracto urinario de repetición orecurrentes (IUR) se definen como la presencia de dos o más episodios de infección del tracto urinario (ITU) en los últimos seis meses o tres o más episodios en los últimos doce meses.

  • •

    Es fundamental diferenciar las IUR en recidivas y reinfecciones para determinar la actitud diagnósticoterapéutica de las mismas.

  • •

    El tratamiento preventivo incluye intervenciones para evitar los factores de riesgo, medidas no antimicrobianas y la antibioterapia.

  • •

    En la cistitis recurrente la profilaxis antibiótica puede ser continua, poscoital o autotratamiento de los episodios.

  • •

    En la mitad de los hombres con IUR la próstata es la fuente de infección.

  • •

    La profilaxis crónica con antibióticos orales de infecciones prostáticas persistentes o recurrentes se utiliza con frecuencia en la práctica clínica, pero faltan datos para avalar su uso.

Palabras clave
Infección del tracto urinario
ITU recurrente
Prevención
Profilaxis
Tratamiento

Identifíquese

¿Aún no es suscriptor de la revista?

Comprar el acceso al artículo

Comprando el artículo el pdf del mismo podrá ser descargado

Teléfono para incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España 932 415 960
Llamadas desde fuera de España +34 932 415 960
Bibliografía
[1]
Delgado MP, Ortega GY. Nefrología al día. Infecciones de la Vías Urinarias y de Trasmisión Sexual. [consultado 13 Jun 2022]. Disponible en: https://www.nefrologiaaldia.org/462.
[2]
G. Torrell, J. Milozzi.
Infecciones del tracto urinario.
AMF., (2013), 9 pp. 124-133
[3]
C. Pigrau.
Infecciones del tracto urinario nosocomiales.
Enferm Infecc Microbiol Clin., (2013), 31 pp. 614-624
[4]
M. De Cueto, L. Aliaga, J.I. Alós, A. Canut, I. Los-Arcos, J.A. Martínez, et al.
Executive summary of the diagnosis and treatment of urinary tract infection: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC).
Enferm Infecc Microbiol Clin., (2017), 35 pp. 314-320
[5]
C. Pigrau-Serrallach.
Infecciones urinarias recurrentes.
Enferm Infecc Microbiol Clin., (2005), 23 pp. 28-39
[6]
National Institute for Health and Care Excellence. Urinary tract infection (recurrent): antimicrobial prescribing. UK. 2018. [consultado 14 Jun 2022]. Disponible en: https://www.nice.org.uk/guidance/ng112.
[7]
H. Lomberg, B. Cedergren, H. Leffler, B. Nilsson, A.S. Carlström, C. Svanborg-Edén.
Influence of blood group on the availability of receptors for attachment of uropathogenic Escherichia coli.
Infect Immun., (1986), 51 pp. 919-926
[8]
D. Scholes, T.M. Hooton, P.L. Roberts, A.E. Stapleton, K. Gupta, W.E. Stamm.
Risk factors for recurrent urinary tract infection in young women.
J Infect Dis., (2000), 182 pp. 1177-1182
[9]
B.I. Yoon, S. Kim, D.S. Han, U.S. Ha, S.J. Lee, H.W. Kim, et al.
Acute bacterial prostatitis: how to prevent and manage chronic infection?.
J Infect Chemother., (2012), 18 pp. 444-450
[10]
Y. Handelsman.
Potential Place of SGLT2 Inhibitors in Treatment Paradigms for Type 2 Diabetes Mellitus.
Endocr Pract., (2015), 21 pp. 1054-1065
[11]
D. Vasilakou, T. Karagiannis, E. Athanasiadou, M. Mainou, A. Liakos, E. Bekiari, et al.
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review meta-analysis.
Ann Intern Med., (2013), 159 pp. 262-274
[12]
S. Kalra, S. Ghosh, A.H. Aamir.
Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.
Indian J Endocrinol Metab., (2017), 21 pp. 210-230
[13]
J. Anger, U. Lee, A.L. Ackerman, R. Chou, B. Chughtai, J.Q. Clemens, et al.
Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline.
J Urol., (2019), 202 pp. 282-289
[14]
J. Peck, J.P. Shepherd.
Recurrent Urinary Tract Infections: Diagnosis, Treatment, and Prevention.
Obstet Gynecol Clin North Am., (2021), 48 pp. 501-513
[15]
A. Aydin, K. Ahmed, I. Zaman, M.S. Khan, P. Dasgupta.
Recurrent urinary tract infections in women.
Int Urogynecol J., (2015), 26 pp. 795-804
[16]
S. Dason, J.T. Dason, A. Kapoor.
Guidelines for the diagnosis and management of recurrent urinary tract infection in women.
Can Urol Assoc J., (2011), 5 pp. 316-322
[17]
European Association of Urology. EAU Guidelines on Urological Infections. The Netherlands.2022. [consultado 15 Jun 2022]. Disponible en: http://uroweb.org/guidelines/compilations-of-all-guidelines.
[18]
T.M. Hooton, M. Vecchio, A. Iroz, I. Tack, Q. Dornic, I. Seksek, et al.
Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial.
JAMA Intern Med, (2018), 178 pp. 1509-1515
[19]
S. Wawrysiuk, K. Naber, T. Rechberger, P. Miotla.
Prevention and treatment of uncomplicated lower urinary tract infections in the era of increasing antimicrobial resistance-non-antibiotic approaches: a systemic review.
Arch Gynecol Obstet., (2019), 300 pp. 821-828
[20]
J.A. Simon, C. Altomare, S. Cort, W. Jiang, J.V. Pinkerton.
Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
J Womens Health (Larchmt)., (2018), 27 pp. 14-23
[21]
C.M. Gill, M.A. Hughes, K.L. LaPlante.
A Review of Nonantibiotic Agents to Prevent Urinary Tract Infections in Older Women.
J Am Med Dir Assoc., (2020), 21 pp. 46-54
[22]
American College of Obstetricians and Gynecologists Committee on Gynecologic Practice; Farrell R. ACOG Committee Opinion No. 659: The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 2016; 127(3).
[23]
R.G. Jepson, J.C. Craig.
Cranberries for preventing urinary tract infections.
Cochrane Database of Systematic Reviews, (2008),
[24]
A. Pietropaolo, P. Jones, M. Moors, B. Birch, B.K. Somani.
Use and Effectiveness of Antimicrobial Intravesical Treatment for Prophylaxis and Treatment of Recurrent Urinary Tract Infections (UTIs): a Systematic Review.
Curr Urol Rep., (2018), 19 pp. 78
[25]
F. Sundén, L. Håkansson, E. Ljunggren, B. Wullt.
Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying.
J Urol., (2010), 184 pp. 179-185
[26]
D. De Vita, S. Giordano.
Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study.
Int Urogynecol J., (2012), 23 pp. 1707-1713
[27]
J.C. Goddard, D.A.W. Janssen.
Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis.
Int Urogynecol J., (2018), 29 pp. 933-942
[28]
G.R. Eldridge, H. Hughey, L. Rosenberger, S.M. Martin, A.M. Shapiro, E. D’Antonio, et al.
Safety and immunogenicity of an adjuvanted Escherichia coli adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results from a first-in-human phase 1 study.
Hum Vaccin Immunother., (2021), 17 pp. 1262-1270
[29]
A.R. Brumbaugh, H.L. Mobley.
Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine.
Expert Rev Vaccines., (2012), 11 pp. 663-676
[30]
N. Sihra, A. Goodman, R. Zakri, A. Sahai, S. Malde.
Nonantibiotic prevention and management of recurrent urinary tract infection.
Nat Rev Urol., (2018), 15 pp. 750-776
[31]
X. Qin, M.E. Coyle, L. Yang, J. Liang, K. Wang, X. Guo, et al.
Acupuncture for recurrent urinary tract infection in women: a systematic review and meta-analysis.
BJOG, (2020), 127 pp. 1459-1468
[32]
A. Flower, L.Q. Wang, G. Lewith, J.P. Liu, Q. Li.
Chinese herbal medicine for treating recurrent urinary tract infections in women.
Cochrane Database of Systematic Reviews, (2015),
[33]
T. Pérez, M. Agüero, I.P. Troz.
Tratamiento y profilaxis de la infección urinaria recurrente en la mujer.
Rev Med Sinerg., (2022), 7 pp. e737
[34]
C. Betschart, W.C. Albrich, S. Brandner, D. Faltin, A. Kuhn, D. Surbek, et al.
Guideline of the Swiss Society of Gynaecology an.d Obstetrics (SSGO) on acute and recurrent urinary tract infections in women, including pregnancy.
Swiss Med Wkly., (2020), pp. w20236
[35]
C. Pigrau.
Formación médica continuada: Infección nosocomial. Fundamentos y actuación clínica Infecciones del tracto urinario nosocomiales.
Enferm Infecc Microbiol Clin., (2013), 31 pp. 614-624
[36]
K. Gupta, T.M. Hooton, P.L. Roberts, W.E. Stamm.
Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women.
[37]
P.L. Dwyer, M. O’Reilly.
Recurrent urinary tract infection in the female.
Curr Opin Obstet Gynecol., (2002), 14 pp. 537-543
[38]
C. Pigrau, L. Escolà-Vergé.
Recurrent urinary tract infections: from pathogenesis to prevention.
Med Clin (Barc)., (2020), 155 pp. 171-177
[39]
Meyrier A, Fekete T. Acute Bacterial Prostatitis. UpToDate. 2016. [consultado 19 Jun 2022].Disponible en: https://www.uptodate.com/contents/chronic-bacterial-prostatitis.
[40]
DynaMed. Chronic Bacterial Prostatitis. EBSCO Information Services. 1995-2016. [consultado 19 Jun 2022].Disponible en: https://www.dynamed.com/condition/chronic-bacterial-prostatitis.
[41]
B.A. Lipsky, I. Byren, C.T. Hoey.
Treatment of bacterial prostatitis.
Clin Infect Dis., (2010), 50 pp. 1641-1652
[42]
C.M. McNaughton, R. MacDonald, T.J. Wilt.
Diagnosis and treatment of chronic abacterial prostatitis: a systematic review.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet], (2000),
[43]
J. Zhang, C. Liang, X. Shang, H. Li.
Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Disease or Symptom?. Current Perspectives on Diagnosis, Treatment, and Prognosis.
Am J Mens Health [Internet]., (2020), 14
[44]
Z.T. Su, J.M. Zenilman, K.S. Sfanos, A.S. Herati.
Management of Chronic Bacterial Prostatitis.
Curr Urol Rep., (2020), 21 pp. 29
[45]
V.J. Sharp, E.B. Takacs, C.R. Powell.
Prostatitis: diagnosis and treatment.
Am Fam Physician., (2010), 82 pp. 397-406
[46]
M.I. Kogan, K.S. Ibishev, Y.L. Naboka, I.A. Gudima, A.K. Ferzauli, R.S. Ismailov, et al.
Antibiotic therapy of chronic bacterial prostatitis is more effective considering antibiotic susceptibility of all pathogens isolated.
Investig Clin Urol., (2022), 63 pp. 325-333
[47]
Grupo de Trabajo de Enfermedades Infeccionas de la semFYC. Manual de enfermedades infecciosas en Atención Primaria. Sociedad Españo- la de Medicina Familiar y Comunitaria. Barcelona. 2017. 4ª ed. [consultado 18 Jun 2022].Disponible en: https://www.semfyc.es/formacion-y-recursos/manual-de-enfermedades-infecciosas-en-atencion-primaria-4a-edicion/.
[48]
G. Perletti, E. Marras, F.M.E. Wagenlehner, V. Magri.
Antimicrobial therapy for chronic bacterial prostatitis.
Cochrane Database of Systematic Reviews, (2013),
[49]
B.C. Gill, D.A. Shoskes.
Bacterial prostatitis.
Curr Opin Infect Dis., (2016), 29 pp. 86-91
[50]
W. Deng, X. Du, W. Zhou, X. Mei, Y. Tian, L. Chen, et al.
Systematic review and meta-analysis: ?-adrenergic receptor blockers in chronic prostatitis.
Ann Palliat Med., (2021), 10 pp. 9870-9878
[51]
G.A. Barbalias, G. Nikiforidis, E.N. Liatsikos.
Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics.
J Urol., (1998), 159 pp. 883-887
[52]
D.S. Schoeb, D. Schlager, M. Boeker, U. Wetterauer, M. Schoenthaler, T.R.W. Herrmann, et al.
Surgical therapy of prostatitis: a systematic review.
World J Urol., (2017), 35 pp. 1659-1668
[53]
I. Karaiskos, L. Galani, V. Sakka, A. Gkoufa, O. Sopilidis, D. Chalikopoulos, et al.
Oral fosfomycin for the treatment of chronic bacterial prostatitis.
J Antimicrob Chemother., (2019), 74 pp. 1430-1437
[54]
A. Toth, F.M. Guercini, D.M. Feldthouse, J.C. Zhang.
Injection therapy for chronic prostatitis: A retrospective analysis of 77 cases.
Arch Ital Urol Androl., (2018), 90 pp. 34-39